改变生活方式和非药物干预措施以改善牛皮关节炎的结果:系统性审查
Louise H Hailey1, Raj Amarnani2, Chris Bundy3
1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.
Clinical therapeutics
|August 4, 2023
概括
这一系统性审查发现,在牛皮性关节炎 (PsA) 中,对非药物治疗的证据有限. 虽然身体活动有望改善疾病活动和福祉,但需要更多的研究来确定PsA患者的有效生活方式修改.
科学领域:
- 类风湿病学 类风湿病学
- 综合医学是一个整体的医学.
- 公共卫生 公共卫生
背景情况:
- 牛皮关节炎 (PsA) 是一种慢性炎症状况,影响多个身体系统,导致显著的发病率,功能限制和心理困扰.
- 目前对PsA的治疗指南主要关注药理干预,对非药理和心理方法的指导有限.
- 需要探索生活方式修改和非药物疗法,以补充现有的治疗方法,并改善患者在PsA.
研究的目的:
- 系统地审查关于生活方式修改和非药物/心理干预措施改善牛皮关节炎 (PsA) 患者治疗结果的有效性的文献.
- 为医疗保健专业人员确定基于证据的指导意见,以确定PsA管理的非药物干预措施.
主要方法:
- 在多个数据库 (例如,MEDLINE,EMBASE,PsycINFO) 进行了系统的文献搜索,搜索了2010年至2021年间发表的研究.
- 包括的研究评估了患有PsA的成年人,并评估了身体活动,饮食,戒烟和补充疗法等干预措施.
- 研究选择,数据提取和偏差风险评估由两位评论员独立进行.
主要成果:
- 八项研究符合纳入标准,包括体育活动,饮食,戒烟和泥治疗.
- 包含的研究在干预,结果测量和研究设计方面表现出显著的异质性 (3项随机对照试验,5项非随机研究).
- 身体活动干预表明,它对PsA患者的疾病活动和心理健康有潜在的积极影响.
结论:
- 目前来自本系统性审查的证据不足以提供关于牛皮关节炎非药物治疗的高质量指导.
- 虽然身体活动似乎有益,但其他生活方式修改和非药物干预措施的有效性在很大程度上仍未确立.
- 进一步严格,精心设计的研究是必不可少的,以制定强有力的治疗建议,在PsA管理中进行非药物和心理干预.
相关概念视频
01:26Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
01:26COPD: Management Using Bronchodilators and Corticosteroids
244
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244
01:27Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
01:26Peripheral Artery Disease IV: Nursing Management
12
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
12
01:23Atherosclerosis IV: Nursing Management
23
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
23
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
14
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
14